Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA)

Vittorio Gebbia, Giuseppe Bronte, Elena Collovà, Emilio Bria, Silvia Novello, Alessandro Follador, Jessica Menis, Massimo Di Maio, Giuseppe Luigi Banna

Risultato della ricerca: Article

4 Citazioni (Scopus)

Abstract

BACKGROUND: A recent pooled analysis of randomized trials indicated significant improvement in overall survival from cisplatin-based adjuvant chemotherapy for non-small cell lung cancer (NSCLC), depending on disease stage (only in stages II and III) and PS (≤ 1). Post-operative radiotherapy (RT) is optional for pN2 tumours. PATIENTS AND METHODS: To evaluate opinions and daily clinical practice of Italian Oncologists about adjuvant treatment of NSCLC, a 46-item questionnaire was delivered via e-mail. RESULTS: Seventy-eight physicians from 68 Centers (out of 98 contacted) returned their questionnaire. Seventy-four, 86, 94, and 78% of them give the indication for adjuvant chemotherapy for stage IIA, IIB, IIIA, and IIIB disease, respectively and 14% in stage IB disease. Stage, PS, and age are taken into consideration evaluating adjuvant approach by 97, 95 and 73%, respectively. Cisplatin-vinorelbine (64%) and cisplatin-gemcitabine (33%), for 4 cycles (81%), are the preferred regimens, while 32% use different regimens. Ninety-two percent indicate RT in pN2 disease and/or positive resection margins. Real Number of patients Needed to Treat (NNT) is probably not completely known/understood and/or used by physicians. CONCLUSIONS: A substantial adherence between clinical daily practice in Italy and scientific progresses is described in this paper, even with some discordances regarding the most appropriate adjuvant chemotherapy regimen.
Lingua originaleEnglish
pagine (da-a)78-88
Numero di pagine11
RivistaLung Cancer
Volume73
Stato di pubblicazionePublished - 2011

Fingerprint

Non-Small Cell Lung Carcinoma
Adjuvant Chemotherapy
Cisplatin
gemcitabine
Radiotherapy
Physicians
Numbers Needed To Treat
Postal Service
Therapeutics
Italy
Survival
Surveys and Questionnaires
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research
  • Pulmonary and Respiratory Medicine

Cita questo

Gebbia, V., Bronte, G., Collovà, E., Bria, E., Novello, S., Follador, A., ... Banna, G. L. (2011). Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA). Lung Cancer, 73, 78-88.

Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA). / Gebbia, Vittorio; Bronte, Giuseppe; Collovà, Elena; Bria, Emilio; Novello, Silvia; Follador, Alessandro; Menis, Jessica; Di Maio, Massimo; Banna, Giuseppe Luigi.

In: Lung Cancer, Vol. 73, 2011, pag. 78-88.

Risultato della ricerca: Article

Gebbia, V, Bronte, G, Collovà, E, Bria, E, Novello, S, Follador, A, Menis, J, Di Maio, M & Banna, GL 2011, 'Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA)', Lung Cancer, vol. 73, pagg. 78-88.
Gebbia V, Bronte G, Collovà E, Bria E, Novello S, Follador A e altri. Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA). Lung Cancer. 2011;73:78-88.
Gebbia, Vittorio ; Bronte, Giuseppe ; Collovà, Elena ; Bria, Emilio ; Novello, Silvia ; Follador, Alessandro ; Menis, Jessica ; Di Maio, Massimo ; Banna, Giuseppe Luigi. / Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA). In: Lung Cancer. 2011 ; Vol. 73. pagg. 78-88.
@article{cce45e4987674ea5a9e1849500fde9f0,
title = "Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA)",
abstract = "BACKGROUND: A recent pooled analysis of randomized trials indicated significant improvement in overall survival from cisplatin-based adjuvant chemotherapy for non-small cell lung cancer (NSCLC), depending on disease stage (only in stages II and III) and PS (≤ 1). Post-operative radiotherapy (RT) is optional for pN2 tumours. PATIENTS AND METHODS: To evaluate opinions and daily clinical practice of Italian Oncologists about adjuvant treatment of NSCLC, a 46-item questionnaire was delivered via e-mail. RESULTS: Seventy-eight physicians from 68 Centers (out of 98 contacted) returned their questionnaire. Seventy-four, 86, 94, and 78{\%} of them give the indication for adjuvant chemotherapy for stage IIA, IIB, IIIA, and IIIB disease, respectively and 14{\%} in stage IB disease. Stage, PS, and age are taken into consideration evaluating adjuvant approach by 97, 95 and 73{\%}, respectively. Cisplatin-vinorelbine (64{\%}) and cisplatin-gemcitabine (33{\%}), for 4 cycles (81{\%}), are the preferred regimens, while 32{\%} use different regimens. Ninety-two percent indicate RT in pN2 disease and/or positive resection margins. Real Number of patients Needed to Treat (NNT) is probably not completely known/understood and/or used by physicians. CONCLUSIONS: A substantial adherence between clinical daily practice in Italy and scientific progresses is described in this paper, even with some discordances regarding the most appropriate adjuvant chemotherapy regimen.",
author = "Vittorio Gebbia and Giuseppe Bronte and Elena Collov{\`a} and Emilio Bria and Silvia Novello and Alessandro Follador and Jessica Menis and {Di Maio}, Massimo and Banna, {Giuseppe Luigi}",
year = "2011",
language = "English",
volume = "73",
pages = "78--88",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA)

AU - Gebbia, Vittorio

AU - Bronte, Giuseppe

AU - Collovà, Elena

AU - Bria, Emilio

AU - Novello, Silvia

AU - Follador, Alessandro

AU - Menis, Jessica

AU - Di Maio, Massimo

AU - Banna, Giuseppe Luigi

PY - 2011

Y1 - 2011

N2 - BACKGROUND: A recent pooled analysis of randomized trials indicated significant improvement in overall survival from cisplatin-based adjuvant chemotherapy for non-small cell lung cancer (NSCLC), depending on disease stage (only in stages II and III) and PS (≤ 1). Post-operative radiotherapy (RT) is optional for pN2 tumours. PATIENTS AND METHODS: To evaluate opinions and daily clinical practice of Italian Oncologists about adjuvant treatment of NSCLC, a 46-item questionnaire was delivered via e-mail. RESULTS: Seventy-eight physicians from 68 Centers (out of 98 contacted) returned their questionnaire. Seventy-four, 86, 94, and 78% of them give the indication for adjuvant chemotherapy for stage IIA, IIB, IIIA, and IIIB disease, respectively and 14% in stage IB disease. Stage, PS, and age are taken into consideration evaluating adjuvant approach by 97, 95 and 73%, respectively. Cisplatin-vinorelbine (64%) and cisplatin-gemcitabine (33%), for 4 cycles (81%), are the preferred regimens, while 32% use different regimens. Ninety-two percent indicate RT in pN2 disease and/or positive resection margins. Real Number of patients Needed to Treat (NNT) is probably not completely known/understood and/or used by physicians. CONCLUSIONS: A substantial adherence between clinical daily practice in Italy and scientific progresses is described in this paper, even with some discordances regarding the most appropriate adjuvant chemotherapy regimen.

AB - BACKGROUND: A recent pooled analysis of randomized trials indicated significant improvement in overall survival from cisplatin-based adjuvant chemotherapy for non-small cell lung cancer (NSCLC), depending on disease stage (only in stages II and III) and PS (≤ 1). Post-operative radiotherapy (RT) is optional for pN2 tumours. PATIENTS AND METHODS: To evaluate opinions and daily clinical practice of Italian Oncologists about adjuvant treatment of NSCLC, a 46-item questionnaire was delivered via e-mail. RESULTS: Seventy-eight physicians from 68 Centers (out of 98 contacted) returned their questionnaire. Seventy-four, 86, 94, and 78% of them give the indication for adjuvant chemotherapy for stage IIA, IIB, IIIA, and IIIB disease, respectively and 14% in stage IB disease. Stage, PS, and age are taken into consideration evaluating adjuvant approach by 97, 95 and 73%, respectively. Cisplatin-vinorelbine (64%) and cisplatin-gemcitabine (33%), for 4 cycles (81%), are the preferred regimens, while 32% use different regimens. Ninety-two percent indicate RT in pN2 disease and/or positive resection margins. Real Number of patients Needed to Treat (NNT) is probably not completely known/understood and/or used by physicians. CONCLUSIONS: A substantial adherence between clinical daily practice in Italy and scientific progresses is described in this paper, even with some discordances regarding the most appropriate adjuvant chemotherapy regimen.

UR - http://hdl.handle.net/10447/100245

M3 - Article

VL - 73

SP - 78

EP - 88

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

ER -